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Abstract: The ability to accurately estimate the sample size required by a stepped-wedge (SW) cluster random-
ized trial (CRT) routinely depends upon the specification of several nuisance parameters. If these parameters
are mis-specified, the trial could be over-powered, leading to increased cost, or under-powered, enhancing
the likelihood of a false negative. We address this issue here for cross-sectional SW-CRTs, analyzed with a
particular linear mixed model, by proposing methods for blinded and unblinded sample size re-estimation (SSRE).
Blinded estimators for the variance parameters of a SW-CRT analyzed using the Hussey and Hughes model are
derived. Then, procedures for blinded and unblinded SSRE after any time period in a SW-CRT are detailed. The
performance of these procedures is then examined and contrasted using two example trial design scenarios. We
find that if the two key variance parameters were under-specified by 50%, the SSRE procedures were able to
increase power over the conventional SW-CRT design by up to 29%, resulting in an empirical power above the
desired level. Moreover, the performance of the re-estimation procedures was relatively insensitive to the timing
of the interim assessment. Thus, the considered SSRE procedures can bring substantial gains in power when the
underlying variance parameters are mis-specified. Though there are practical issues to consider, the procedure’s
performance means researchers should consider incorporating SSRE in to future SW-CRTs.
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1 Introduction
A stepped-wedge (SW) cluster randomised trial (CRT) involves the sequential roll-out of an intervention across
several clusters over multiple time periods, with the time period in which a cluster begins receiving the intervention
determined at random. Recent papers have established methods for sample size determination in the case of
cross-sectional [11] and cohort [10] designs, for trials with multiple levels of clustering and for incomplete block
SW-CRTs [9].
Undeniably, there has been a growing interest in the design, and in particular, it has now become associated
with scenarios in which there is a belief that the trial’s experimental intervention will be effective [4, 16]. Given
this commonly held belief, it may come as a surprise that a recent literature review determined that in 31% of the
SW-CRTs completed by February 2015, there was no significant effect of the experimental intervention on any of
the trials primary outcome measures [7]. To guard against this, implicitly assuming this failure rate was due to the
experimental interventions being futile, methodology for the incorporation of interim analyses in SW-CRTs was
recently described [8]. One other possible explanation is that the studies have been false negatives. A high false
negative rate could be associated with SW-CRTs having been under-powered. Methodology available to deter-
mine the sample size required by SW-CRTs is dependent upon the specification of the values of several nuisance
parameters (e.g., the between cluster and residual variances). In practice, it may be difficult to provide accurate
estimates for these factors, and their mis-specification may be leading to under-powered studies. Alternatively, if
these parameters are being mis-specified such that SW-CRTs have been over-powered, there may have been more
measurements taken than actually required, leading to unnecessary cost.
A common approach to addressing the specification of nuisance parameters in the trial design literature is the
use of a sample size re-estimation (SSRE) procedure. Each such method has essentially the same intention: to
alleviate the issue of pre-specifying nuisance parameters by allowing them to be re-estimated during the trial, and
the required sample size adjusted [17]. Broadly speaking they can be sub-categorised into blinded or unblinded
techniques, with regulatory agencies preferring to maintain the blind when possible so as to not risk compromising
the validity of a trial [12]. Blinded SSRE methodology is today available for a range of settings (e.g., Friede
and Kieser [5], Golkowski et al. [6], and Kunz et al. [15]), with each such procedure typically conferring highly
desirable trial operating characteristics.
However, whilst some results exist on SSRE in multi-centre [13] and parallel group CRTs [19], no work has
established methodology for SSRE in SW-CRTs, with the increased complexity in the design of SW-CRTs ne-
cessitating a specialised approach. In this article, we address this by developing and exploring the performance
of both blinded and unblinded SSRE procedures for cross-sectional SW-CRTs. In particular a commonly con-
sidered linear mixed model will be utilised for data analysis, blinded estimators of the key variance parameters
are developed. The performance of a SSRE procedure based on these blinded estimators is then compared to an
unblinded approach, as a function of their various control parameters, and the parameters of the underlying model.
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We then conclude with a discussion of possible extensions to our approach, as well as logistical factors that must
be considered when incorporating SSRE in to SW-CRTs.
2 Methods
2.1 Notation, hypotheses and analysis
We consider a scenario in which a cross-sectional SW-CRT is to be carried out in C clusters over T time periods,
with n individuals recruited per cluster per time period. That is, we assume data will be accrued on new patients in
each cluster in each time period. We do not restrict our attention to ‘balanced’ SW-CRTs however; clusters need
not start in the control condition, conclude in the experimental condition, and there does not need to be an equal
number of clusters switching to the experimental intervention in each time period.
We assume that the accumulated data will be normally distributed, and the following linear mixed model will
be utilised for data analysis, as proposed by Hussey and Hughes [11]
yijk = µ+ pij + τXij + ci + ijk. (1)
Here
• yijk is the response of the kth individual (k = 1, . . . , n), in the ith cluster (i = 1, . . . , C), in the jth time
period (j = 1, . . . , T );
• µ is an intercept term;
• pij is a fixed effect for the jth time period (with pi1 = 0 for identifiability);
• τ is a fixed treatment effect for the experimental intervention relative to the control;
• Xij is the binary treatment indicator for the ith cluster and jth time period. That is, Xij = 1 if cluster i
receives the intervention in time period j. We denote by X the matrix formed from the Xij , and by X(t) the
first t columns of X;
• ci ∼ N(0, σ2c ) is a random effect for cluster i;
• ijk ∼ N(0, σ2e) is the individual-level error.
We denote the vector of fixed effects by β = (µ, pi2, . . . , piT , τ)T . Moreover, we indicate the design matrix linking
β to the vector of responses yT ,n, from the set of time periods T , given an allocation matrix X , and a per cluster
per period sample size of n, by DT ,n. We similarly denote the covariance matrix of yT ,n, given σ2c and σ
2
e , by
Cov(yT ,n, yT ,n | σ2c , σ2e) = ΣT ,n,σ2c ,σ2e . As noted in Hussey and Hughes [11], ΣT ,n,σ2c ,σ2e is an |T |n × |T |n
block diagonal matrix.
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We perform a one-sided hypothesis test for τ
H0 : τ ≤ 0, H1 : τ > 0,
and assume that it is desired to have a type-I error rate of α when τ = 0, and to have power to reject H0 of 1− β
when τ = δ, for some specified δ > 0. Note that SSRE procedures for two-sided hypotheses are also easily
achievable.
Finally, we assume that hypothesised values for the variance parameters σ2c and σ
2
e have been provided, which
we denote by σ˜2c and σ˜
2
e . Alternatively, a value for one of these parameters, and a value for the intra-cluster
correlation (ICC) ρ, ρ˜ = σ˜2c/(σ˜
2
c + σ˜
2
e), could be specified, such that σ˜
2
c and σ˜
2
e can still be determined. Given
these values, we assume a sample size calculation has been performed (using the methods to be described shortly)
and values for X and n (and thus also C and T since dim(X) = C × T ) have subsequently been specified. For
reasons to be elucidated below we refer to this n as ninit.
With the above, a conventional SW-CRT can be conducted as follows. We recruit ninit individuals per cluster
per time period, with the experimental intervention allocated according to the matrix X . On completion, we use
restricted error maximum likelihood (REML) estimation to acquire an estimate of τˆ , denoted τˆ , and a value for
Iˆ = {Var(τˆ)}−1. Next, we compute the test statistic T = τˆ Iˆ1/2, and reject H0 if T > e, where e is the solution to
α =
∫ ∞
e
ϕ{x, 0, 1, ν}dx,
ν = ninitCT − C − T.
Here, ϕ{x, µ,Λ, ν} is the probability density function of a t-distribution with mean µ, covariance Λ, and
degrees of freedom ν, evaluated at x. Moreover, specifically we take ν to be the degrees of freedom in a corre-
sponding balanced multi-level ANOVA design. Later, we will discuss the implications of this and other possible
ways to prescribe ν.
We next detail how the above can be extended to allow SSRE to be incorporated in to the design.
2.2 Sample size re-estimation procedures
A single SSRE interim analysis is included in the SW-CRT design after a designated time period t ∈ {1, . . . , T−1}.
Specifically, we assume that the trial is conducted as per matrixX and the value ninit for time periods 1, . . . , t. After
this, we compute estimates for the variance parameters, σˆ2c and σˆ
2
e , based upon the accumulated data. Below, we
detail how exactly this is achieved in the blinded and unblinded procedures. Here, we discuss how these estimates
are then used.
Explicitly, we search numerically as follows to determine the required per cluster per period sample size for
the remainder of the trial, nreest, to convey the desired power if σ2c = σˆ
2
c and σ
2
e = σˆ
2
e . Thus, the number of clusters
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remains fixed throughout the trial; it is the per cluster per period sample size that is adjusted. We consider possible
alternatives to this in the discussion.
Firstly, suppose nreest has been chosen, then time periods t+1, . . . , T of the trial are conducted using the matrix
X for treatment allocation, and recruiting nreest individuals per cluster per period. At the end of the trial the linear
mixed model (1) with REML estimation are utilised to acquire τˆ and Iˆ as above. The test statistic T = τˆ Iˆ1/2 is
again determined, and H0 rejected if T > e, but e is now the solution to
α =
∫ ∞
e
ϕ{x, 0, 1, νnreest}dx,
νnreest = ninitCt+ nreestC(T − t)− C − T.
Here, νnreest is the degrees of freedom in a balanced multi-level ANOVA design if a sample size of ninit is used per
cluster per period in time periods 1, . . . , t, and a sample size of nreest is used per cluster per period in time periods
t+ 1, . . . , T .
The power to reject H0 when τ = δ, for a particular nreest, can thus be estimated at the interim as
P(Reject H0 | nreest) =
∫ ∞
e
ϕ{x, δI1/2, 1, νnreest}dx,
where I is given by the inverse of element [T + 1, T + 1] of the following matrix
(
DT{1,...,t},ninitΣ
−1
{1,...,t},ninit,σˆ2c ,σˆ2eD{1,...,t},ninit+
DT{t+1,...,T},nreestΣ
−1
{t+1,...,T},nreest,σˆ2c ,σˆ2eD{t+1,...,T},nreest
)−1
.
This matrix arises as the theoretical covariance matrix of the maximum likelihood estimator of β when a sample
size of ninit is used per cluster per period in time periods 1, . . . , t, and a sample size of nreest is used per cluster per
period in time periods t+ 1, . . . , T .
Therefore, we can compute the required value for nreest by searching for the minimal integer solution to the
following equation
P(Reject H0 | nreest) ≥ 1− β.
In fact, to make our SSRE procedures more applicable in practice, and to guard against unrealistically large values
for nreest, we carry out the remaining periods of the trial recruiting nfinal individuals per cluster per time period,
where
nfinal =

nmin : nreest < nmin,
nreest : nmin ≤ nreest ≤ nmax,
nmax : nmax < nreest.
Here, nmin and nmax are designated values for the minimal and maximal allowed number of patients per cluster per
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period following the re-estimation. These could be chosen for example based upon the practical attainable values
of n for a particular trial.
Finally, following determination of nfinal, the remainder of the trial and ensuant analysis is conducted as de-
scribed above, to determine whether to reject H0.
Note that the sample size required by a classical fixed sample SW-CRT design, given an allocation matrix X ,
can be determined using the above by treating ninit as a variable rather than a fixed parameter, and searching for
the minimal ninit such that P(Reject H0 | 0) ≥ 1 − β when t = T . Alternatively, ninit could be specified and the
matrix X determined for the desired power.
All that remains to be elucidated in the above procedure is the means of determining the estimates σˆ2c and σˆ
2
e .
As discussed, we describe both blinded and unblinded approaches to their specification.
The unblinded procedure is as follows. After time period t, we fit the following model to the accumulated data
using REML estimation
yijk =

µ+ pij + τXij + ci + ijk : sum(X(t)) > 0 and t > 1,
µ+ pij + ci + ijk : sum(X(t)) = 0 and t > 1,
µ+ τXij + ci + ijk : sum(X(t)) > 0 and t = 1,
µ+ ci + ijk : sum(X(t)) = 0 and t = 1.
Here, sum(X(t)) > 0 is included as a qualifier to indicate the term Xijτ should appear in our model as at least
one cluster has been administered the experimental intervention in some time period. Similarly, t > 1 indicates
period effects should be accounted for in the model. From the REML estimator, we attain our values for σˆ2c and
σˆ2e immediately, and use them in the above algorithm to determine nfinal.
For the blinded procedure, we define
S21 =
C∑
i=1
t∑
j=1
ninit∑
k=1
(Yijk − Y¯ (t)... )2,
S2Ct =
C∑
i=1
t∑
j=1
ninit∑
k=1
(Yijk − Y¯ij.)2,
where
Y¯ (t)... =
1
ninitCt
C∑
i=1
t∑
j=1
ninit∑
k=1
Yijk,
Y¯ij. =
1
ninit
ninit∑
k=1
Yijk.
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Then, in the Appendix we derive that in the absence of period effects
E(S21) = σ2e +
ninitCt
ninitCt− 1
(
1− 1
C
)
σ2c +
ninitτ
2
ninitCt− 1 sum(X
(t))
− n
2
initτ
2
ninitCt(ninitCt− 1) sum(X
(t))2,
E(S2Ct) = σ2e .
Given a particular choice for τ in the above, which we shall denote τ∗, these equations are used to estimate σ2c and
σ2e as follows
• Compute S21 and S2Ct using the formulae above and the accrued data.
• Define f(S21 , σ2e , X(t), n, τ) as
f(S21 , σ
2
e , X
(t), n, τ) =
nCt− 1
nCt
C
C − 1
{
S21 − σ2e −
nτ2∗
nCt− 1 sum(X
(t))
+
n2τ2∗
nCt(nCt− 1) sum(X
(t))2
}
.
• Set σˆ2e = S2Ct and σˆ2c = max{f(S21 , σˆ2e , X(t), ninit, τ∗), 0}.
We then utilise the algorithm from earlier for determining the value of nfinal.
Note that therefore, in the absence of period effects, if τ∗ = τ , the above are unbiased estimators for the
variance parameters.
For further clarity, the full unblinded and blinded SSRE procedures are detailed algorithmically in the Ap-
pendix.
2.3 Simulation study
With the above considerations, a SSRE trial design scenario is fully specified given D , where
D = {X, t, σ2c , σ2e , σ˜2c , σ˜2e , α, β, δ, µ,pi, τ, nmin, nmax, B} ∪ I{B=1}{τ∗}.
Here, pi = (pi2, . . . , piT )T is the vector of period effects, and B is a binary indicator variable that takes the value 1
if blinded SSRE is utilised, and the value 0 if unblinded SSRE is utilised. Finally, IA is the indicator function on
event A.
Given D we can simulate a SW-CRT utilising this SSRE procedure by generating random multivariate normal
observations. From this, the empirical rejection rate (ERR) of a particular scenario can be estimated by performing
a large number of replicates simulations. To this end, define Rs(D) to be 1 if the result of replicate s of a trial
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simulated according to scenario D is to reject H0, and 0 otherwise. For any number of replicates r, the ERR for
scenario D is
ERR(D) =
1
r
r∑
s=1
Rs(D).
In this article, r = 105 for all considered scenarios.
In what follows, we consider the ERR in a wide variety of scenarios. However, many of the parameters in D
remain fixed. In particular, they are set based on two motivating trial design scenarios.
Firstly, Bashour et al. [2] conducted a SW-CRT to assess the effect of training doctors in communication skills
on women’s satisfaction with doctor-woman relationship during labour and delivery. The trial utilised a balanced
complete block SW-CRT design, enrolling four hospitals, and gathering data over five time periods. The final
analysis estimated the between cluster and residual variances to be σ2c = 0.02 and σ
2
e = 0.51, respectively. For
these variance parameters, the utilised design would have required 70 patients per cluster per time period for the
trials desired type-I and type-II error rates of 0.05 and 0.1 respectively, when powering for a clinically relevant
difference of 0.2, using the methods above. Thus in Trial Design Setting (TDS) 1 we fix σ2c = 0.02, σ
2
e = 0.51,
α = 0.05, β = 0.1, and δ = 0.2. Moreover, C = 4, T = 5, and X is such that a single cluster switches to the
experimental intervention in time periods two through five. Furthermore, we assume for this example that trialists
would not want the per cluster per period sample size to drop post re-estimation, and thus set nmin = ninit. Finally,
we always take nmax = 200. This value was chosen as a fair compromise of an attainable n (noting that the trial
was easily able to recruit 100 patients per cluster per time period), and a value large enough such that for most
considered values of σ˜2c , σˆ
2
e and t, the trial should be able to meet the power requirement.
The parameters of TDS2 are based upon the typical characteristics of SW-CRTs according to a recent review
[7]. Precisely, we take, as in Grayling et al. [8], σ2c = 1/9, σ
2
e = 1, α = 0.05, β = 0.2 and δ = 0.24, to consider a
more modest value for the ICC of ρ = 0.1. In this case, to differ from TDS1, we do allow the per cluster per time
period sample size to drop following re-estimation, setting nmin = 0.5ninit and nmax = 20. Finally, we set C = 20,
T = 9, and X such that three clusters switch to the experimental intervention in time periods two through five, and
two clusters in time periods six through nine.
Additionally, for simplicity, in both TDSs we take µ = 0 and τ∗ = 0. We therefore consider the effect of
different choices for t, σ˜2c , σ˜
2
e , pi, τ , and B. Moreover, we primarily focus upon the following three combinations
for the assumed variance parameters σ˜2c and σ˜
2
e
• Scenario 1: When the variance components are under-specified by 50%; σ˜2c = 0.5σ2c , σ˜2e = 0.5σ2e .
• Scenario 2: When the variance components are correctly specified; σ˜2c = σ2c , σ˜2e = σ2e .
• Scenario 3: When the variance components are over-specified by 50%; σ˜2c = 1.5σ2c , σ˜2e = 1.5σ2e .
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Software to perform the above simulations is available from https://sites.google.com/site/jmswason/supplementary-
material.
3 Results
3.1 Performance for varying σ˜2c and σ˜2e
To begin, we consider how the SSRE procedures perform as σ2c and σ
2
e are mis-specified to varying degrees. For
simplicity, we set pi = 0, and take t = 3 and t = 5 for TDS1 and TDS2 respectively. Precisely, we explore
(σ˜2c , σ˜
2
e) ∈ {0.5σ2c , σ2c , 1.5σ2c} × {0.5σ2e , σ2e , 1.5σ2e}, with τ = 0; the empirical type-I error rate (ETI), or τ = δ;
the empirical power (EP). Table 1 depicts the results, displaying the empirical rejection rates of the re-estimation
procedures and the corresponding fixed sample SW-CRT design.
Table 1: The empirical type-I error rate and power of the blinded and unblinded re-estimation procedures, along
with the corresponding fixed sample SW-CRT design are shown. Results are given for trial design settings 1 and
2, for a selection of possible values for the assumed variance parameters, when t = 3 and t = 5 in trial design
settings 1 and 2 respectively.
Empirical type-I error rate Empirical power
σ˜2c σ˜
2
e Blinded Unblinded Fixed Blinded Unblinded Fixed
Trial Design Setting 1
0.5σ2c 0.5σ
2
e 0.0575 0.0572 0.0623 0.8527 0.8711 0.6905
0.5σ2c σ
2
e 0.0564 0.0570 0.0595 0.8993 0.9005 0.8930
0.5σ2c 1.5σ
2
e 0.0544 0.0556 0.0577 0.9718 0.9714 0.9689
σ2c 0.5σ
2
e 0.0564 0.0572 0.0622 0.8536 0.8712 0.7030
σ2c σ
2
e 0.0553 0.0565 0.0596 0.9055 0.9061 0.9024
σ2c 1.5σ
2
e 0.0536 0.0529 0.0572 0.9760 0.9758 0.9748
1.5σ2c 0.5σ
2
e 0.0577 0.0588 0.0642 0.8523 0.8719 0.7130
1.5σ2c σ
2
e 0.0572 0.0563 0.0579 0.9082 0.9105 0.9060
1.5σ2c 1.5σ
2
e 0.0519 0.0531 0.0563 0.9780 0.9772 0.9738
Trial Design Setting 2
0.5σ2c 0.5σ
2
e 0.0505 0.0509 0.0526 0.7419 0.8039 0.6250
0.5σ2c σ
2
e 0.0499 0.0485 0.0523 0.7762 0.8108 0.8119
0.5σ2c 1.5σ
2
e 0.0497 0.0495 0.0512 0.8529 0.8551 0.9076
σ2c 0.5σ
2
e 0.0507 0.0493 0.0526 0.7415 0.8008 0.6221
σ2c σ
2
e 0.0500 0.0501 0.0512 0.7773 0.8069 0.8094
σ2c 1.5σ
2
e 0.0491 0.0486 0.0507 0.8854 0.8846 0.9293
1.5σ2c 0.5σ
2
e 0.0498 0.0492 0.0530 0.7390 0.8009 0.6247
1.5σ2c σ
2
e 0.0495 0.0489 0.0512 0.7761 0.8084 0.8118
1.5σ2c 1.5σ
2
e 0.0486 0.0484 0.0518 0.8858 0.8851 0.9308
In general, assuming larger values for the variance parameters leads to an increased EP and a decreased ETI,
as would be expected.
In TDS1, for certain values of the assumed variance parameters there is large inflation of the ETI above the
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nominal level. This is an issue common to both the SSRE procedures and the fixed design, with the maximal
inflation observed for σˆ2c = 1.5σ
2
c , σˆ
2
e = 0.5σ
2
e in the fixed design where the ETI is 0.0642. Finally, in this setting,
the blinded procedure most often attains the smallest ETI, but this comes at a cost to its EP relative to the unblinded
approach.
In contrast, for TDS2 the SSRE procedures routinely control the ETI to approximately the desired level, with
the blinded and unblinded methods displaying similar ETIs. Though it is smaller than for TDS1, the fixed design
still displays some inflation to the ETI. The unblinded procedure again typically has higher EP than the blinded
approach. However, the difference between the two procedures EP is now more pronounced. In fact, in most
instances, the blinded procedure does not attain the desired power. In this case, because the SSRE procedures are
allowed to lower the per cluster per period sample size at the interim analysis, for some assumed values of the
variance parameters they have an EP smaller than the fixed design.
Overall, it is clear that for many assumed values of the two variance components, the SSRE procedures have a
far higher EP than the corresponding fixed SW-CRT design, with comparable if not preferable ETIs. For example,
when σ˜2c = 0.5σ
2
c and σ˜
2
e = 0.5σ
2
e in TDS2, the blinded procedure has an EP of 0.8039, whilst the corresponding
conventional SW-CRT design has an EP of only 0.6250; an increase of 29%.
3.2 Performance for varying t
Next, we assess the impact upon the ETI and EP of the choice of the SSRE point t. As above, we set pi = 0.
However, we now focus on the three assumed variance scenarios given in Section 2.3.
Table 2 displays the ETI and EP of the blinded and unblinded SSRE procedures when τ = 0 and τ = δ
respectively, for t ∈ {2, 3, 4} in TDS1 and t ∈ {3, 5, 7} in TDS2. There is no observable trend to the ETI as
t is increased in either TDS. For most of the considered assumed values for the variance parameters, the ETI is
comparable for each t.
For TDS1, t = 3 leads to the largest EP in all instances. In TDS2, the allowance to lower the per cluster per
period sample size results in each of the considered values for t attaining the maximal power for some assumed
variance combination.
In some cases, it is clear that placing the re-estimation point later in to the trial can cause a substantial loss of
power. For example, when σ˜2c = 0.5σ
2
c and σ˜
2
e = 0.5σ
2
e in TDS1, the unblinded procedure has power close to the
nominal level of 0.8711 when t = 3, but this drops to 0.7690 for t = 4.
3.3 Performance for varying pi
In the above, we have considered only pi = 0. This is a useful scenario to explore, since often period effects will
be expected to be, and ultimately will be, small. However, the estimators used in our blinded SSRE procedure
are only unbiased in the absence of period and treatment effects, whilst our unblinded SSRE procedure is only
asymptotically invariant to the value of these effects. It is thus important to assess the effect of non-zero period
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Table 2: The empirical type-I error rate and empirical power of the blinded and unblinded re-estimation procedures
are shown. Precisely, results are given for trial design settings 1 and 2, for a selection of possible values for the
assumed variance parameters, as a function of the re-estimation time point t.
Empirical type-I error rate Empirical power
Trial Design Setting 1
Procedure σ˜2c σ˜
2
e t = 2 t = 3 t = 4 t = 2 t = 3 t = 4
Blinded 0.5σ2c 0.5σ
2
e 0.0597 0.0575 0.0507 0.8454 0.8527 0.7682
Blinded σ2c σ
2
e 0.0566 0.0553 0.0582 0.9049 0.9055 0.9050
Blinded 1.5σ2c 1.5σ
2
e 0.0558 0.0519 0.0545 0.9762 0.9780 0.9765
Unblinded 0.5σ2c 0.5σ
2
e 0.0620 0.0572 0.0499 0.8582 0.8711 0.7690
Unblinded σ2c σ
2
e 0.0567 0.0565 0.0578 0.9076 0.9061 0.9057
Unblinded 1.5σ2c 1.5σ
2
e 0.5238 0.0531 0.0536 0.9760 0.9772 0.9757
Trial Design Setting 2
Procedure σ˜2c σ˜
2
e t = 3 t = 5 t = 7 t = 3 t = 5 t = 7
Blinded 0.5σ2c 0.5σ
2
e 0.0514 0.0505 0.0479 0.7323 0.7419 0.7251
Blinded σ2c σ
2
e 0.0495 0.0500 0.0491 0.7637 0.7773 0.7959
Blinded 1.5σ2c 1.5σ
2
e 0.0480 0.0486 0.0490 0.8391 0.8858 0.9151
Unblinded 0.5σ2c 0.5σ
2
e 0.0515 0.0509 0.0477 0.8019 0.8039 0.7475
Unblinded σ2c σ
2
e 0.0502 0.0501 0.0503 0.8108 0.8069 0.8067
Unblinded 1.5σ2c 1.5σ
2
e 0.0481 0.0484 0.0502 0.8393 0.8851 0.9145
effects on the SSRE procedures. Here, we explore this for τ = 0.
Precisely, we consider the ETI of our SSRE procedures when the value of pij (j = 1, . . . , T ) in each replicate
scenario is drawn randomly as pij ∼ N(0, σ2pi). Note that these are unscaled pij , we still force pi1 = 0 for
identifiability purposes when fitting the linear mixed model (1). We then conduct these simulations for several
values of σ2pi , to determine how the strength of the period effects affects the ETI. Moreover, we achieve this for the
three assumed variance scenarios given in Section 2.3, taking t = 3 in TDS1 and t = 5 in TDS2.
Figures 1 and 2 display the results of these simulations. It is evident that, allowing for Monte Carlo error, the
value of σ2pi appears to have little impact upon the ETI as σ
2
pi is increased for any of the considered scenarios.
Moreover, performance is clearly comparable between the blinded and unblinded procedures, if not arguably
better in the blinded approach.
4 Discussion
In this article, we have presented blinded and unblinded SSRE procedures for cross-sectional SW-CRTs. These
methods should assist with scenarios in which there is difficultly in determining a trial’s required sample size
because of the need to specify values for several nuisance parameters. We were able to demonstrate that, at least
for the considered scenarios, the SSRE procedures could increase power substantially over a conventional SW-CRT
design when the variance parameters were under-estimated.
Unfortunately, in TDS1 there were instances of substantial inflation to the ETI rate using our SSRE procedures.
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Figure 1: The empirical type-I error rate of the blinded and unblinded sample size re-estimation procedures is
shown for the three considered variance parameter scenarios in TDS1 as a function of the variance of the period
effects σ2pi . Error bars indicate the Monte Carlo error.
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Figure 2: The empirical type-I error rate of the blinded and unblinded sample size re-estimation procedures is
shown for the three considered variance parameter scenarios in TDS2 as a function of the variance of the period
effects σ2pi . Error bars indicate the Monte Carlo error.
This was not surprising given the extremely low number of clusters in this scenario, with past research highlighting
issues in such a setting [18, 8]. Additionally, it follows results observed for parallel-group CRTs [19]. To address
this, one could use the Kenward-Roger approach to the specification of the degrees of freedom in the final analysis
[14]. Alternatively, an alpha-level adjustment procedure, as considered for example by Golkowski et al. [6] could
be utilised. With either of these methods, one may anticipate that the the type-I error rate could be controlled
more closely to the nominal level, but the design still attain a higher power than the corresponding fixed sample
approach.
Unfortunately, in TDS2 the blinded SSRE routinely did not display an EP above the nominal level. To combat
this, one could employ a sample size inflation factor, as proposed by Zucker et al. [20]. This has been demonstrated
to be highly effective in a range of trial design setting (e.g., Friede and Kieser [5], Golkowski et al. [6]). Using it,
it could be possible for the preferable blinded SSRE procedure to provide the desired power.
We observed that the ETI and EP were similar for several choices of t, particularly in TDS1, but the EP was
sometimes substantially lower if the re-estimation point was late in the trial. This should not be surprising, since a
larger value of t implies less time to re-adjust for any mis-specifications in the variance parameters. Of course, a
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smaller value for t implies less data has been accumulated, and so we may expect on average less accurate estimates
for σ2c and σ
2
e . One may therefore suggest an intermediate option, such as t = 3 in TDS1, to be preferable.
Though we anticipated that the unblinded procedure would have more desirable properties in the case of non-
zero period effects, we actually found that the performance of the two types of SSRE procedure were similar.
Consequently, it may be possible even in the case of strong period effects for the preferable blinded SSRE proce-
dure to be utilised. Of course, researchers should always extensively examine the operating characteristics of any
SSRE procedure in a range of scenarios before utilisation to verify this to be the case.
As well as determining the influence of non-zero period effects, this should also include assessing a designs
sensitivity to the choice of nmin and nmax. In particular, whilst it may be preferable to have nmin < ninit, this
could have negative consequences upon the EP. This has been discussed previously for conventional parallel arm
individually randomised trials (see, for example, Bowden and Mander [3]). It was evident here in TDS2, where
for example the blinded SSRE procedure had an EP below the desired level when σ2e was specified correctly, but
the fixed design did not. This does however confer an advantage that when σ˜2e = 1.5σ
2
e the SSRE procedures were
able to reduce the power to closer to the nominal level compared to the fixed design. Likewise, increasing the value
of nmax may seem beneficial, but one then needs both to be able to find more patients to recruit in the later periods,
and also to be able to logistically handle a larger sample size. This may be a problem particularly for scenarios
where the SW-CRT design is being utilised because of resource constraints.
There are several practical factors that must be considered before SSRE is incorporated in to a SW-CRT design.
Primarily, our methodology is dependent upon data from all clusters being available for analysis immediately
following period t. The efficiency of the procedures would suffer if this were not the case. Therefore, it would be
important for measures to be put in place for efficient data collection, storage, and analysis. In addition, there may
be some instances where SSRE is not realistic. For example, if the intervention was a planned roll-out that is part
of a larger programme implementation. A trialist must consider their scenario carefully before utilising SSRE.
Several possible extensions to our procedures are possible. Firstly, we here only addressed cross-sectional
SW-CRT designs analysed with the Hussey and Hughes model. Though the majority of SW-CRT research has
been set in this domain, it would be beneficial to also establish methods to incorporate SSRE in to cohort designed
SW-CRT, different endpoints of interest, or indeed different analysis models. Whilst it would be relatively simple
to explore the performance of an unblinded procedure in these settings, methodology for blinded re-estimation
would be more complex. Similar statements also hold for allowing variable cluster sizes, and also incorporating
the interim estimated value for τ in to the re-estimation procedure.
Additionally, we considered here a scenario in which the number of clusters remained fixed throughout the trial;
adjusting only the per cluster per period sample size following the re-estimation point. One could also explore the
performance of a procedure that increases the value of C following re-estimation, creating an incomplete-block
SW-CRT. For scenarios in which patients are hard to come by, but clusters are not, this would be a useful extension.
It is worth noting that our procedures are actually applicable to any cross-sectional CRT design to be analysed
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with the Hussey and Hughes model. This means, for example, that it would allow also the incorporation of SSRE
in to a cluster randomised crossover trial, which is being increasingly acknowledged in the trials community as a
useful design [1].
Regardless of the practical considerations discussed above, and the possible future avenues of extension to
our methods, it is clear that the ability to include a SSRE point in to SW-CRT designs is a useful addition to the
methodologists toolbox.
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Appendix
A.1. Blinded estimators
In this section, we derive the expected value of the blinded estimators given in Section 2.2.
To begin, we observe that for equation (1), for i1, i2 ∈ {1, . . . , C}, j1, j2 ∈ {1, . . . , T}, and k1, k2 ∈
{1, . . . , n}
Cov(Yi1j1k1 , Yi2j2k2) = δi1i2δj1j2δk1k2σ
2
e + δi1i2σ
2
c ,
as is stated in Hussey and Hughes [11]. Moreover, using the standard “.” notation to indicate when a variable has
been summed over, and denoting Sa = {(x, y) ∈ (1, . . . , a)× (1, . . . , a) : x 6= y}
Cov
(
Y¯ij., Y¯ij.
)
= Var
(
Y¯ij.
)
,
= Var
(
1
n
n∑
k=1
Yijk
)
,
=
1
n2
Var
(
n∑
k=1
Yijk
)
,
=
1
n2
 n∑
k=1
Var(Yijk) +
∑
(k1,k2)∈Sn
Cov (Yijk1 , Yijk2)
 ,
=
1
n2
(σ2e + σ2c ) + ∑
(k1,k2)∈Sa
σ2c
 ,
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=
1
n2
[
n(σ2e + σ
2
c ) + n(n− 1)σ2c
]
,
=
1
n
[
σ2e + nσ
2
c
]
.
Additionally, taking
Nt =
C∑
i=1
t∑
j=1
n = nCt,
with N = NT , and recalling X(t) is the matrix formed by restricting X to its first t columns, if
Y¯ (t)... =
1
Nt
C∑
i=1
t∑
j=1
n∑
k=1
Yijk,
we have that
cov
(
Y¯ (t)... , Y¯
(t)
...
)
= var
(
Y¯ (t)...
)
,
= var
 1
Nt
C∑
i=1
t∑
j=1
n∑
k=1
Yijk
 ,
=
1
N2t
var
 C∑
i=1
t∑
j=1
n∑
k=1
Yijk
 ,
=
1
N2t
 C∑
i=1
t∑
j=1
n∑
k=1
var(Yijk)
+
∑
(i1,i2)∈SC
∑
(j1,j2)∈St
∑
(k1,k2)∈Sn
cov (Yi1j1k1 , Yi2j2k2)
 ,
=
1
N2t
[
Nt(σ
2
e + σ
2
c ) + nCt(nt− 1)σ2c
]
,
=
1
Nt
(
σ2e +
Nt
C
σ2c
)
.
Now, after time period t, two sensible variances can be computed; the variance of all response values gathered thus
far (the one sample variance, S21 ), and the variance of the response values from each cluster in each time period
thus far from their corresponding mean values (the Ct sample variance, S2Ct). Explicitly, we have
(Nt − 1)S21 =
C∑
i=1
t∑
j=1
n∑
k=1
(
Yijk − Y¯ (t)...
)2
,
=
 C∑
i=1
t∑
j=1
n∑
k=1
Y 2ijk
−NtY¯ (t)2... ,
(Nt − Ct)S2Ct =
C∑
i=1
t∑
j=1
n∑
k=1
(
Yijk − Y¯ij.
)2
,
=
C∑
i=1
t∑
j=1
[
n∑
k=1
Y 2ijk − nY¯ 2ij.
]
.
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Without loss of generality, we can assume that µ = 0. By definition, we know that
E
[
(N − Ct)S2Ct
]
= (N − Ct)σ2e .
Furthermore, exploiting the fact that X2ij = Xij
E
[
(Nt − 1)S21
]
=
 C∑
i=1
t∑
j=1
n∑
k=1
E(Y 2ijk)
−NtE(Y¯ (t)2... ),
=

C∑
i=1
t∑
j=1
n∑
k=1
[
var(Yijk) + E(Yijk)2
]
−Nt
[
var(Y¯ (t)... ) + E(Y¯ (t)... )2
]
,
=

C∑
i=1
t∑
j=1
n∑
k=1
[
(σ2e + σ
2
c ) + (pij +Xijτ)
2
]
−Nt
 1Nt
(
σ2e +
Nt
C
σ2c
)
+
 1
Nt
C∑
i=1
t∑
j=1
n∑
k=1
(pij +Xijτ)
2
 ,
= Nt(σ
2
e + σ
2
c ) +
C∑
i=1
t∑
j=1
n∑
k=1
(pij +Xijτ)
2 −
(
σ2e +
Nt
C
σ2c
)
− 1
Nt
 C∑
i=1
t∑
j=1
n∑
k=1
(pij +Xijτ)
2 ,
= (Nt − 1)σ2e +Nt
(
1− 1
C
)
σ2c +
C∑
i=1
t∑
j=1
n∑
k=1
pi2j
+
C∑
i=1
t∑
j=1
n∑
k=1
(Xijτ)
2 + 2
C∑
i=1
t∑
j=1
n∑
k=1
pijXijτ
− 1
Nt
 C∑
i=1
t∑
j=1
n∑
k=1
pij
2 − 1
Nt
 C∑
i=1
t∑
j=1
n∑
k=1
Xijτ
2
− 2
Nt
 C∑
i=1
t∑
j=1
n∑
k=1
pij
 C∑
i=1
t∑
j=1
n∑
k=1
Xijτ
 ,
= (Nt − 1)σ2e +Nt
(
1− 1
C
)
σ2c + nC
t∑
j=1
pi2j
+ nτ2
C∑
i=1
t∑
j=1
X2ij + 2nτ
C∑
i=1
t∑
j=1
pijXij
− n
2C2
Nt
 t∑
j=1
pij
2 − n2τ2
Nt
 C∑
i=1
t∑
j=1
Xij
2
− 2n
2Cτ
Nt
 t∑
j=1
pij
 C∑
i=1
t∑
j=1
Xij
 ,
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= (Nt − 1)σ2e +Nt
(
1− 1
C
)
σ2c + nC(pi
(t) · pi(t))
+ nτ2sum(X(t)) + 2nτsum(X(t)pi(t))
− n
2C2
Nt
sum(pi(t))2 − n
2τ2
Nt
sum(X(t))2
− 2n
2Cτ
Nt
sum(pi(t))sum(X(t)),
where pi(t) = (pi1, . . . , pit)T , and sum(A) for a matrix A indicates the sum of all of its elements. Therefore, in the
absence of period effects (pi(t) = 0), we have
E
(
S21
)
= σ2e +
Nt
Nt − 1
(
1− 1
C
)
σ2c +
nτ2
Nt − 1 sum(X
(t))− n
2τ2
Nt(Nt − 1) sum(X
(t))2,
E(S2Ct) = σ2e ,
as given in the main part of the paper.
5.1 Sample size re-estimation procedures: algorithm
Here, we provide a complete point-by-point algorithm for how the blinded and unblinded re-estimation procedures
should be conducted.
Firstly, our blinded SSRE procedure is as follows
1. Specify values for X , α, β, δ, σ˜2c , σ˜
2
e , t, τ∗, nmin and nmax.
2. Perform an initial sample size determination, to acquire ninit, assuming σ2e = σ˜
2
e and σ
2
c = σ˜
2
c .
3. Conduct the trial up to the end of time period t, recruiting ninit individuals per cluster per period.
4. Compute S21 and S
2
Ct.
5. Set σˆ2e = S
2
Ct and σˆ
2
c = max{f(S21 , σˆ2e , X(t), ninit, τ∗), 0}.
6. Compute the exact required per cluster per period sample size, nreest, for the rest of the trial to imply the
desired operating characteristics assuming σ2c = σˆ
2
c and σ
2
e = σˆ
2
e . Then, set nfinal as follows
nfinal =

nmin : nreest < nmin,
nreest : nmin ≤ nreest ≤ nmax,
nmax : nmax < nreest.
7. Conduct periods t+ 1, . . . , T of the trial, recruiting nfinal patients per cluster per period.
8. Perform a final unblinded analysis on all accumulated data using equation (1) to determine efficacy.
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Finally, our unblinded SSRE procedure is as follows
1. Specify values for X , α, β, δ, σ˜2c , σ˜
2
e , t, τ∗, nmin and nmax.
2. Perform an initial sample size determination, to acquire ninit, assuming σ2e = σ˜
2
e and σ
2
c = σ˜
2
c .
3. Conduct the trial up to the end of time period t, recruiting ninit individuals per cluster per period.
4. Fit the following model to all accumulated data using REML estimation
yijk =

µ+ ci + pij +Xijτ + ijk : if sum(X(t)) > 0 and t > 1,
µ+ ci + pij + ijk : if sum(X(t)) = 0 and t > 1,
µ+ ci +Xijτ + ijk : if sum(X(t)) > 0 and t = 1,
µ+ ci + ijk : if sum(X(t)) = 0 and t = 1.
.
5. From the fitted model obtain the estimates σˆ2c and σˆ
2
e .
6. Compute the exact required per cluster per period sample size, nreest, for the rest of the trial to imply the
desired operating characteristics assuming σ2c = σˆ
2
c and σ
2
e = σˆ
2
e . Then, set nfinal as follows
nfinal =

nmin : nreest < nmin,
nreest : nmin ≤ nreest ≤ nmax,
nmax : nmax < nreest.
7. Conduct periods t+ 1, . . . , T of the trial, recruiting nfinal patients per cluster per period.
8. Perform a final unblinded analysis on all accumulated data using equation (1) to determine efficacy.
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